Anaplastic Large Cell Lymphoma (ALCL) - Likely Diagnosis and Treatment
Based on the histologic description of highly pleomorphic cells with foamy histiocytes and plasma cells, this presentation is most consistent with Anaplastic Large Cell Lymphoma (ALCL), and first-line treatment should be CHOP-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) with or without rituximab depending on CD20 expression status.
Diagnostic Reasoning
The key histologic features described—highly pleomorphic cells accompanied by foamy histiocytes and numerous plasma cells—point toward ALCL rather than classical Hodgkin lymphoma (cHL). While both can show pleomorphic cells, the specific cellular milieu differs:
- Classical Hodgkin lymphoma typically shows Hodgkin-Reed-Sternberg (HRS) cells comprising only 0.1-1% of the cell population, with a background of lymphocytes, histiocytes, eosinophils, plasma cells, and fibroblasts 1
- ALCL characteristically presents with large pleomorphic or anaplastic cells with irregularly shaped nuclei and abundant pale/eosinophilic cytoplasm, often with clusters of reactive lymphocytes 2
Critical Diagnostic Steps
Immunophenotyping is mandatory to confirm the diagnosis:
- CD30 expression must be present in ≥75% of tumor cells for ALCL diagnosis 2
- Check CD15, CD20, CD3, CD4, CD8 to distinguish from cHL (which is typically CD15+/CD30+/CD20-) 1
- Evaluate for ALK-1 (p80) and t(2;5) translocation status, as this impacts prognosis 2
- Assess for epithelial membrane antigen (EMA) and cutaneous lymphocyte antigen (HECA-452) if cutaneous involvement is suspected 2
First-Line Treatment Approach
For Systemic ALCL (Non-Cutaneous)
Standard chemotherapy regimen:
- CHOP or CHOP-like regimens are the backbone of treatment
- Consider adding rituximab if CD20-positive (though ALCL is typically CD20-negative)
- Treatment duration: typically 6-8 cycles depending on stage and response 1
For Primary Cutaneous ALCL
If the presentation is limited to skin without systemic involvement:
- Localized disease: Radiotherapy (30-50 Gy) or surgical excision 2, 3
- Multifocal cutaneous disease: Consider systemic chemotherapy as above 3
Staging Requirements Before Treatment
Complete staging workup must include:
- Contrast-enhanced CT scan of chest, abdomen, and pelvis
- PET-CT for metabolic assessment and accurate staging
- Bone marrow biopsy (mandatory if PET-CT not available; optional if PET-CT performed) 4
- Complete blood count, LDH, blood chemistry
- Screening for HBV, HCV, HIV 4
Important Caveats and Pitfalls
Differential Diagnosis Considerations
Transformed Mycosis Fungoides: If patches/plaques are present, consider MF with transformation where CD30 may be expressed by large tumor cells 2
Hodgkin Lymphoma: The immunophenotype is critical—cHL shows CD15+/CD30+/CD20-, while ALCL typically shows CD30+ with variable T-cell markers 1
Systemic ALCL with cutaneous involvement: If ALK-1 positive or t(2;5) present, suspect systemic disease rather than primary cutaneous form 2
Treatment Modifications
- Age >60 years: Avoid BEACOPP regimens due to increased treatment-related mortality; use CHOP-based therapy 4, 1
- Cardiac/pulmonary dysfunction: Obtain baseline cardiac and pulmonary function tests before anthracycline-based therapy 4
- Fertility preservation: Discuss sperm banking or oocyte/ovarian tissue cryopreservation before treatment initiation 4
Response Assessment
- Interim PET-CT after 2-4 cycles to assess chemosensitivity
- End-of-treatment PET-CT to confirm complete metabolic response
- Achieving negative PET should be the goal, as this correlates with improved clinical outcomes 4
Relapsed/Refractory Disease
For patients who fail first-line therapy: